191 related articles for article (PubMed ID: 7665243)
1. Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ.
Murphy DS; McHardy P; Coutts J; Mallon EA; George WD; Kaye SB; Brown R; Keith WN
Int J Cancer; 1995 Feb; 64(1):18-26. PubMed ID: 7665243
[TBL] [Abstract][Full Text] [Related]
2. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer.
Coene ED; Schelfhout V; Winkler RA; Schelfhout AM; Van Roy N; Grooteclaes M; Speleman F; De Potter CR
Virchows Arch; 1997 May; 430(5):365-72. PubMed ID: 9174626
[TBL] [Abstract][Full Text] [Related]
3. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis.
Murphy DS; Hoare SF; Going JJ; Mallon EE; George WD; Kaye SB; Brown R; Black DM; Keith WN
J Natl Cancer Inst; 1995 Nov; 87(22):1694-704. PubMed ID: 7473818
[TBL] [Abstract][Full Text] [Related]
4. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
[TBL] [Abstract][Full Text] [Related]
5. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
Järvinen TA; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
Am J Pathol; 2000 Mar; 156(3):839-47. PubMed ID: 10702400
[TBL] [Abstract][Full Text] [Related]
6. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates.
McManus DT; Patterson AH; Maxwell P; Humphreys MW; Anderson NH
Mol Pathol; 1999 Apr; 52(2):75-7. PubMed ID: 10474685
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.
Orsaria M; Khelifa S; Buza N; Kamath A; Hui P
J Clin Pathol; 2013 Dec; 66(12):1070-5. PubMed ID: 23908451
[TBL] [Abstract][Full Text] [Related]
9. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of chromosome aneuploidy in tissue sections of preinvasive breast carcinomas using interphase cytogenetics.
Visscher DW; Wallis TL; Crissman JD
Cancer; 1996 Jan; 77(2):315-20. PubMed ID: 8625240
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic significance of chromosome 17 polysomy in breast cancer].
Lü YL; Zhong M; Liu L; Wei LX; Zhao P
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):88-91. PubMed ID: 18681318
[TBL] [Abstract][Full Text] [Related]
13. Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breast carcinomas: relation to morphology, cell proliferation and expression of breast cancer-related genes.
Fiche M; Avet-Loiseau H; Maugard CM; Sagan C; Heymann MF; Leblanc M; Classe JM; Fumoleau P; Dravet F; Mahé M; Dutrillaux B
Int J Cancer; 2000 Sep; 89(5):403-10. PubMed ID: 11008201
[TBL] [Abstract][Full Text] [Related]
14. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
[TBL] [Abstract][Full Text] [Related]
15. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.
Varga Z; Tubbs RR; Wang Z; Sun Y; Noske A; Kradolfer D; Bosshard G; Jochum W; Moch H; Öhlschlegel C
Breast Cancer Res Treat; 2012 Apr; 132(3):925-35. PubMed ID: 21698407
[TBL] [Abstract][Full Text] [Related]
16. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
17. A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: comparison with HER-2/CEP17 ratio system.
Mrhalova M; Kodet R
J Cancer Res Clin Oncol; 2007 May; 133(5):321-9. PubMed ID: 17165026
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between aneuploidy of chromosome 17 and amplification of HER-2/neu gene in the different histological type of breast cancer].
Kuroso K; Ueda Y; Mori Y
Rinsho Byori; 2004 Nov; 52(11):897-9. PubMed ID: 15658468
[TBL] [Abstract][Full Text] [Related]
19. Histopathologic analysis of chromosome aneuploidy in ductal carcinoma in situ.
Visscher D; Jimenez RE; Grayson M; Mendelin J; Wallis T
Hum Pathol; 2000 Feb; 31(2):201-7. PubMed ID: 10685634
[TBL] [Abstract][Full Text] [Related]
20. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
